Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rezolute, Inc. - Common Stock (NV)
(NQ:
RZLT
)
3.855
-0.155 (-3.87%)
Delayed Quote
Updated: 10:36 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rezolute, Inc. - Common Stock (NV)
< Previous
1
2
3
4
5
6
7
Next >
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
May 28, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
May 13, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 05, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
May 01, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute, Inc. Announces Closing of Underwritten Offering
April 25, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
↗
April 23, 2025
Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.
Via
Benzinga
The market is filled with gapping stocks in Wednesday's session.
↗
April 23, 2025
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
What's going on in today's pre-market session
↗
April 23, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
April 23, 2025
Via
Benzinga
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
April 23, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
April 23, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Top movers analysis in the middle of the day on 2025-04-21: top gainers and losers in today's session.
↗
April 21, 2025
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 21, 2025
Via
Benzinga
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
March 26, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
March 24, 2025
Via
Benzinga
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
February 12, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
February 04, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
January 31, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 07, 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
December 03, 2024
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
November 07, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
November 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
September 19, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
↗
September 09, 2024
FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 study. Enrollment expected to start in 2025 with topline data by mid-year.
Via
Benzinga
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
September 09, 2024
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
August 27, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
August 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 31, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 27, 2024
Additional $6.7M in funding resulting in approximately $67M in gross proceeds
From
Rezolute, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
